1092952-98-1

Basic information

• Product Name: ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate
• CAS NO: 1092952-98-1
• Molecular Weight: 424.293
• Mol File: 1092952-98-1.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate(1092952-98-1)
• EPA Substance Registry System: ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate(1092952-98-1)

Safety Data

• Hazardous Substances Data: 1092952-98-1(Hazardous Substances Data)

Usage

Description

Ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate is a complex chemical compound that features an ethyl ester group, a dihydropyrimidine ring, and various substituents such as bromine, fluorine, and thiazole. Its intricate structure may confer potential pharmacological properties, suggesting that it could be a candidate for further research and development as a pharmaceutical agent.

Uses

Used in Pharmaceutical Industry:
Ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate is used as a potential pharmaceutical agent for its possible pharmacological properties. ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate's unique structural features, including the presence of a dihydropyrimidine ring and various substituents, may contribute to its potential therapeutic applications. However, further research and testing are necessary to fully understand its properties and explore its potential uses in medicine.

Upstream product

• 59142-68-6 2-bromo-4-fluorobenzaldehyde 
• 141-97-9 ethyl acetoacetate 
• 64-17-5 ethanol 
• 247037-82-7 1,3-thiazole-2-carboximidamide hydrochloride 

Downstream Products

• 1092953-04-2 ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(thiazol-2-yl)-1,4-dihydro-pyrimidine-5-carboxylate 
• 1571215-69-4 1-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)pyrrolidine-2-carboxylic acid 
• 1571215-73-0 1-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)piperidine-2-carboxylic acid 
• 1571217-44-1 1-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)-4-methylpiperazine-2-carboxylic acid 
• 1571211-74-9 4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic acid 
• 1571212-59-3 (2R,3S)-4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)-2-methylmorpholine-3-carboxylic acid 
• 1571213-34-7 methyl 4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylate 
• 1571214-96-4 isopropyl 4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydro-pyrimidin-4-yl)methyl)morpholine-3-carboxylate 
• 1571212-39-9 ethyl 4-(2-bromo-4-fluorophenyl)-6-((3-carbamoylmorpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate 
• 1571217-89-4 ethyl 4-(2-bromo-4-fluorophenyl)-6-((3-(methylcarbamoyl)morpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate 
• 1571219-25-4 ethyl 4-(2-bromo-4-fluorophenyl)-6-(((S)-2-(hydroxymethyl)morpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate 
• 1571211-95-4 4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-2-carboxylic acid 
• 1571212-14-0 2-(4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-3-yl)acetic acid 
• 1571214-87-3 2-(4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acetic acid 

Relevant articles and documents

Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors

Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors. This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs. X-ray crystallographic study of analogue 12 (HAP_R01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen bonding interactions with capsid protein and coordinated waters. The representative analogue 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further development as oral anti-HBV infection agent.

Dihydropyrimidine-spiro derivative as well as preparation method and application thereof

The invention provides a dihydropyrimidine-spiro derivative as well as a preparation method and application thereof. The compound has a structure as shown in a formula I. The invention further relates to a preparation method of the compound with the structure shown in the formula I, a pharmaceutical composition and application of the compound in preparation of anti-HBV drugs.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.